[HTML][HTML] Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives
MG Ferrara, V Di Noia, E D'Argento, E Vita, P Damiano… - Cancers, 2020 - mdpi.com
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …
patients, despite platinum-based combination chemotherapy, the majority of patients …
Management and future directions in non-small cell lung cancer with known activating mutations
Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …
[HTML][HTML] Advanced-stage non–small cell lung cancer: advances in thoracic oncology 2018
In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …
Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition
Detection of molecular aberrations driving the biology and the clinical behavior of advanced
non-small cell lung cancer (NSCLC) allows the adoption of specific therapeutic strategies …
non-small cell lung cancer (NSCLC) allows the adoption of specific therapeutic strategies …
[HTML][HTML] Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …
leading cause of cancer related-death worldwide. It is now recognized that a significant …
Advanced non–small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations
Personalized therapy based on actionable molecular markers has completely transformed
the therapeutic landscape in advanced non–small cell lung cancer (NSCLC). In less than 15 …
the therapeutic landscape in advanced non–small cell lung cancer (NSCLC). In less than 15 …
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
P Maione, PC Sacco, A Sgambato… - … in medical oncology, 2015 - journals.sagepub.com
The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …
pathways are mediated by druggable protein kinases has led to a revolutionary change in …
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects
Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
[HTML][HTML] Personalizing therapy with targeted agents in non-small cell lung cancer
R Dienstmann, P Martinez, E Felip - Oncotarget, 2011 - ncbi.nlm.nih.gov
In the last 6 years, since the first reports of an association between somatic mutations in
epidermal growth factor receptor (EGFR) exons 19 and 21 and response to EGFR tyrosine …
epidermal growth factor receptor (EGFR) exons 19 and 21 and response to EGFR tyrosine …
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …